Duloxetine
Is It Right for You?
A complete guide to Duloxetine — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Duloxetine?
Duloxetine is a serotonin-noradrenaline reuptake inhibitor (SNRI) -- a class of antidepressant that works on two neurotransmitter systems simultaneously. It is one of the most versatile psychiatric and pain medications available, licensed in the UK for depression, generalised anxiety disorder, diabetic peripheral neuropathic pain, and stress urinary incontinence -- a broader range of indications than most antidepressants.
Unlike SSRIs, which act primarily on serotonin, duloxetine has balanced and potent activity on both serotonin and noradrenaline reuptake. This dual action not only contributes to its antidepressant and anxiolytic effects but also underpins its effectiveness as a pain-modulating agent -- making it particularly valuable for patients whose depression or anxiety is accompanied by significant physical symptoms or chronic pain conditions.
Duloxetine was first approved in the early 2000s and is available generically and under the brand names Cymbalta and Yentreve (the latter specifically for stress urinary incontinence). It is available as gastro-resistant capsules, which protect the active ingredient from stomach acid and ensure consistent absorption.
Duloxetine is a prescription-only medication in the UK. A licensed clinician must assess your symptoms, medical history, and current medications before it can be prescribed -- which can now be done quickly and conveniently through a telehealth consultation.
What Conditions Is Duloxetine Used For?
Duloxetine is licensed for a wider range of conditions than most antidepressants, and is also used off-label for several others:
a first-line treatment option for moderate to severe depression in adults; the dual serotonin and noradrenaline action may offer advantages for patients with prominent physical symptoms of depression such as fatigue, pain, and somatic complaints.
licensed for the treatment of persistent, excessive anxiety and worry in adults; effective for both the psychological and physical symptoms of anxiety including muscle tension, fatigue, and concentration difficulties
licensed for the management of chronic nerve pain caused by diabetic neuropathy; duloxetine is a first-line recommended treatment for this indication in NICE guidelines.
widely used for the widespread musculoskeletal pain, fatigue, cognitive difficulties, and sleep disturbance associated with fibromyalgia; licensed for this indication in the USA.
including chronic low back pain and osteoarthritis pain; NICE recommends duloxetine as an option for chronic primary pain and chronic secondary musculoskeletal pain where other treatments have been insufficient.
licensed under the brand name Yentreve for the treatment of moderate to severe stress urinary incontinence in women; works by increasing urethral sphincter tone through enhanced noradrenergic signalling.
Like all antidepressants and SNRIs, duloxetine does not produce immediate relief of depressive or anxiety symptoms. Most patients begin to notice benefit after 2--4 weeks of consistent treatment, with full therapeutic effects typically apparent after 4--8 weeks. For pain conditions, improvement may take several weeks. It is important not to stop treatment prematurely if little benefit is noticed in the early weeks, and to discuss expectations with your clinician before starting.
How Does Duloxetine Work?
Duloxetine works by inhibiting the reuptake of two key neurotransmitters -- serotonin and noradrenaline -- simultaneously and with broadly balanced potency. This distinguishes it from SSRIs, which primarily target serotonin, and gives it a wider range of therapeutic applications.
Serotonin reuptake inhibition -- by blocking the serotonin transporter (SERT), duloxetine increases the availability of serotonin in the synapse, enhancing serotonergic neurotransmission in brain circuits involved in mood regulation, emotional processing, and anxiety. This contributes to its antidepressant and anxiolytic effects.
Noradrenaline reuptake inhibition -- by blocking the noradrenaline transporter (NET), duloxetine increases noradrenaline availability in the synapse. Noradrenaline plays a key role in alertness, motivation, energy, and concentration -- symptoms that are frequently impaired in depression. Noradrenergic activity also contributes to duloxetine's efficacy for pain, as noradrenaline is a key neurotransmitter in descending pain inhibitory pathways -- the brain and spinal cord's natural mechanism for suppressing pain signals from the body. By enhancing noradrenergic tone in these pathways, duloxetine increases the brain's capacity to dampen pain signals before they reach conscious awareness.
This same noradrenergic mechanism explains duloxetine's effectiveness for stress urinary incontinence -- noradrenaline enhances the tone of the pudendal nerve, which controls the external urethral sphincter, thereby improving bladder control during coughing, sneezing, and physical exertion.
Duloxetine has minimal affinity for muscarinic, histaminergic, dopaminergic, or adrenergic receptors -- the receptor systems responsible for many of the side effects seen with older tricyclic antidepressants. This accounts for its generally more tolerable side effect profile compared to that class of drugs, though it carries more side effects than SSRIs due to its additional noradrenergic activity.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Duloxetine capsules must be swallowed whole. The capsules are gastro-resistant (enteric-coated) to protect the active ingredient from stomach acid and ensure consistent absorption. Do not crush, chew, or open the capsules, as this destroys the protective coating and may cause irritation of the mouth and oesophagus, as well as erratic absorption.
Duloxetine can be taken with or without food, though taking it with food may help reduce nausea in the early weeks of treatment.
Take duloxetine at the same time each day. Once-daily dosing allows considerable flexibility in timing -- most patients take it in the morning, though evening dosing is also acceptable. Consistency is more important than the specific time.
Start at a low dose and increase gradually. For anxiety and pain indications, starting at 30 mg for 1--2 weeks before increasing to 60 mg helps significantly reduce early side effects, particularly nausea. Do not increase the dose faster than directed.
Do not stop duloxetine suddenly. Duloxetine is associated with a well-recognised discontinuation syndrome -- symptoms can be significant and include dizziness, nausea, electric shock-like sensations ("brain zaps"), irritability, and flu-like feelings. The dose must be tapered gradually under medical supervision when stopping treatment.
Allow adequate time to assess effectiveness. A full therapeutic trial of at least 4--8 weeks at an adequate dose is necessary before concluding whether duloxetine is working. Dose adjustments should be guided by your clinician.
Side Effects of Duloxetine
Duloxetine is generally well tolerated, though it tends to cause more side effects than SSRIs due to its additional noradrenergic activity. Most side effects are most prominent in the first 1--2 weeks of treatment and diminish as the body adjusts.
- Nausea (very common, particularly early in treatment -- usually improves after 1--2 weeks)
- Dry mouth
- Headache
- Dizziness
- Fatigue or somnolence
- Constipation
- Decreased appetite
- Increased sweating
- Insomnia or disturbed sleep
- Sexual dysfunction -- reduced libido, delayed ejaculation, anorgasmia
- Increased blood pressure (particularly at higher doses)
- Palpitations
- Serotonin syndrome -- agitation, confusion, rapid heart rate, high temperature, muscle rigidity, and tremor; most likely when combined with other serotonergic drugs; potentially life-threatening
- Suicidal thoughts or worsening depression -- particularly in children, adolescents, and young adults under 25 in the early weeks of treatment or after a dose change; requires close monitoring
- Hypertensive crisis -- duloxetine's noradrenergic activity can raise blood pressure; rarely this can be severe, particularly at high doses or in patients with pre-existing hypertension
- Hepatotoxicity -- liver damage including hepatitis and jaundice; rare but reported; more likely in patients with pre-existing liver disease or heavy alcohol use
- Hyponatraemia (low sodium) -- particularly in elderly patients; presents as confusion, headache, and weakness; in severe cases can cause seizures
- Severe allergic reaction -- rash, facial or throat swelling, difficulty breathing; rare but requires immediate emergency treatment
- Severe skin reactions -- Stevens-Johnson Syndrome; very rare
- Angle-closure glaucoma -- duloxetine can cause pupil dilation, which may trigger acute angle-closure glaucoma in susceptible individuals; seek urgent care if sudden eye pain or visual changes develop
- Mania or hypomania -- rare; worsening or new onset of elevated mood, impulsivity, or reduced need for sleep; requires immediate review
Duloxetine is associated with one of the more pronounced discontinuation syndromes among antidepressants. Symptoms including dizziness, nausea, "brain zaps" (electric shock-like sensations in the head), irritability, anxiety, and flu-like feelings can emerge within hours of a missed dose and can be significantly distressing. Never stop duloxetine abruptly. A gradual taper -- sometimes over several weeks or months depending on the duration and dose -- is essential. Discuss a tapering plan with your clinician well in advance of stopping treatment.
Drug Interactions
Duloxetine is metabolised primarily by the liver enzymes CYP1A2 and CYP2D6, and is itself a moderate inhibitor of CYP2D6. This creates a range of clinically important interactions. Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting duloxetine.
Combining duloxetine with MAOIs can cause a potentially fatal serotonin syndrome or hypertensive crisis. Duloxetine must not be started within 14 days of stopping an MAOI, and an MAOI must not be started within 5 days of stopping duloxetine. This combination is absolutely contraindicated.
Combining duloxetine with other serotonergic agents significantly increases the risk of serotonin syndrome. This combination requires careful clinical consideration and close monitoring. St John's Wort should be avoided entirely.
Duloxetine is a moderate inhibitor of CYP2D6 and can raise blood levels of drugs metabolised by this pathway. Of particular note: duloxetine reduces the conversion of tamoxifen to its active metabolite, potentially reducing its effectiveness as a breast cancer treatment. Alternative antidepressants should be considered in patients taking tamoxifen.
Duloxetine may affect the pharmacokinetics of warfarin and, through its effects on platelet serotonin, increase bleeding risk. INR should be monitored closely when starting, stopping, or adjusting duloxetine in patients on warfarin.
Important Warnings
Antidepressants including duloxetine are associated with an increased risk of suicidal thoughts and behaviour in children, adolescents, and young adults under 25, particularly during the first few weeks of treatment or after a dose change. Duloxetine is not licensed for use in children or adolescents. Patients in the at-risk age group and their carers should monitor closely for worsening depression, agitation, irritability, or new suicidal thoughts, and contact a clinician immediately if these occur.
Duloxetine's dual serotonergic and noradrenergic activity means it carries a meaningful risk of serotonin syndrome when combined with other serotonergic medications. This is a potentially life-threatening emergency requiring immediate medical treatment. Symptoms include agitation, confusion, rapid heart rate, high temperature, muscle rigidity, and tremor. Any patient starting duloxetine alongside other serotonergic drugs must be counselled about this risk.
Duloxetine discontinuation syndrome can be severe and prolonged. Dizziness, nausea, "brain zaps," irritability, vivid dreams, and anxiety can emerge quickly after missed doses and may persist for weeks during tapering. Patients should never stop duloxetine abruptly and should plan any discontinuation carefully with their clinician, with a tapering schedule that may take several months in patients who have been on treatment long-term. This is not a sign of addiction but reflects the brain's adaptation to the medication.
Duloxetine's noradrenergic activity can raise blood pressure and heart rate. Blood pressure should be measured before starting treatment and monitored periodically thereafter, particularly at higher doses or in patients with pre-existing hypertension or cardiovascular disease. If significant blood pressure elevation occurs, dose reduction or discontinuation may be necessary.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Duloxetine FAQs
Yes. A licensed clinician can assess your symptoms, medical history, and current medications via a telehealth consultation and prescribe duloxetine if it is clinically appropriate. Prescriptions are typically sent to your preferred pharmacy the same day. For new diagnoses, your clinician will advise on monitoring, follow-up, and expectations for treatment.
SSRIs act primarily on serotonin reuptake. Duloxetine is an SNRI -- it inhibits the reuptake of both serotonin and noradrenaline with broadly balanced potency. The additional noradrenergic action gives duloxetine advantages for treating pain conditions (diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain), physical symptoms of depression (fatigue, pain, somatic complaints), and stress urinary incontinence -- indications for which SSRIs are generally less effective. The trade-off is a slightly higher side effect burden, particularly nausea, sweating, and blood pressure effects.
Most patients notice some initial improvement in sleep, energy, or appetite within the first 1--2 weeks, but the full antidepressant and anxiolytic effect typically takes 4--8 weeks. For pain conditions, improvement may take a similar timeframe. Some patients require a dose increase before they experience full benefit. Persisting with treatment for an adequate trial period before drawing conclusions is essential
Yes. Smoking induces the liver enzyme CYP1A2, which is one of the primary pathways for duloxetine metabolism. Smokers may have duloxetine blood levels approximately one third lower than non-smokers at the same dose, which can reduce effectiveness. If you stop smoking while taking duloxetine, blood levels may rise and side effects may increase -- your clinician should be made aware so that monitoring and potential dose adjustment can be arranged.
Duloxetine can be used in elderly patients but requires more careful monitoring. Older patients are at higher risk of hyponatraemia (low sodium), falls due to dizziness, and blood pressure changes. Doses should generally be started low and increased cautiously. Renal and hepatic function should be assessed before and during treatment, as impairment of either increases the risk of drug accumulation and side effects.
Both duloxetine and venlafaxine are SNRIs, but they differ in their receptor profiles. Venlafaxine acts more selectively on serotonin at lower doses and only achieves balanced SNRI activity at higher doses. Duloxetine has more balanced serotonin and noradrenaline activity across its entire dose range. Duloxetine also has a specific licence for pain conditions (diabetic neuropathy) and stress urinary incontinence that venlafaxine does not. Both are associated with discontinuation syndromes, though venlafaxine's shorter half-life can make its discontinuation syndrome more abrupt. Your clinician will choose the most appropriate SNRI based on your individual condition and profile.